LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP

Atherosclerosis. 2011 Feb;214(2):373-6. doi: 10.1016/j.atherosclerosis.2010.11.029. Epub 2010 Nov 26.

Abstract

Objective: We sought to determine whether concurrently high levels of HDL cholesterol and CRP predict initial cardiovascular events in women, and to assess additional risk involving two genes encoding proteins involved in reverse cholesterol transport.

Methods: A graphical approach identified high-risk subgroups in a population-based female cohort. Polymorphism-associated risk was assessed for CETP (TaqIB [rs708272]) and LPL (D9N [rs1801177]) using multivariable analysis adjusted for clinical parameters and biomarkers.

Results: A high HDL-C/high CRP high-risk subgroup was identified. Multivariable modeling revealed D9N as predicting subgroup cardiovascular disease risk directly (minor allele-carriers versus major allele homozygotes: HR 5.16, 95% CI 1.43-18.54, p = 0.012) and through interaction with TaqIB (highest risk in minor allele carriers of both polymorphisms).

Conclusions: In women with high HDL-C and high CRP levels, an LPL polymorphism associated with risk and interacted with a CETP polymorphism such that the highest risk occurred in subjects with presumably decreased activities of both proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / enzymology
  • Cardiovascular Diseases / genetics*
  • Cardiovascular Diseases / mortality
  • Chi-Square Distribution
  • Cholesterol Ester Transfer Proteins / genetics*
  • Cholesterol, HDL / blood*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Homozygote
  • Humans
  • Kaplan-Meier Estimate
  • Lipoprotein Lipase / genetics*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Phenotype
  • Polymorphism, Genetic*
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Up-Regulation

Substances

  • Biomarkers
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • C-Reactive Protein
  • LPL protein, human
  • Lipoprotein Lipase